|1.||Blessing, John A: 4 articles (08/2002 - 01/2002)|
|2.||Plaxe, Steven C: 4 articles (08/2002 - 01/2002)|
|3.||Ames, Matthew M: 3 articles (10/2005 - 08/2002)|
|4.||Reid, Joel M: 3 articles (10/2005 - 08/2002)|
|5.||Adjei, Alex A: 2 articles (02/2003 - 08/2002)|
|6.||Bajorin, D F: 2 articles (08/2000 - 08/2000)|
|7.||Bekaii-Saab, Tanios: 1 article (04/2011)|
|8.||Kraut, Eric H: 1 article (04/2011)|
|9.||Kuebler, John Philip: 1 article (04/2011)|
|10.||Ramaswamy, Bhuvaneswari: 1 article (04/2011)|
08/15/1990 - "Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice."
11/01/2000 - "Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study."
01/01/1998 - "Pyrazoloacridine (PZA) has antitumor activity in several in vitro and in vivo tumor systems, and was selected for testing in clinical trials by the National Cancer Institute (NCI). "
01/01/1998 - "Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers."
03/01/1998 - "Pyrazoloacridine (PA), an acridine congener with an unknown mechanism of action, has shown selective activity against solid tumor cells, cytotoxicity in noncycling and hypoxic cells, and promising antitumor activity in Phase I clinical trials. "
10/01/2005 - "The phase II dose of the pyrazoloacridine/carboplatin combination is pyrazoloacridine 400 mg/m(2) in combination with carboplatin AUC of 5. Antitumor activity in patients with recurrent gliomas was limited. "
10/01/2005 - "Pyrazoloacridine (PZA), a rationally synthesized acridine derivative, has shown promising antitumor activity against glioma lines in combination with platinum compounds. "
10/01/2005 - "Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial."
10/01/2005 - "The primary objectives of study 3 were to determine the efficacy of the pyrazoloacridine/carboplatin combination in patients with recurrent gliomas, to further assess the toxicity of the combination, and to evaluate the impact of enzyme-inducing anticonvulsants on the pyrazoloacridine metabolism. "
10/01/2005 - "The objectives of studies 1 and 2 were to (a) assess the safety and toxicity and to establish the phase II dose of the pyrazoloacridine/carboplatin combination for recurrent glioma patients on P450 inducing anticonvulsants, and (b) to confirm the phase II dose for patients not on P450 inducing anticonvulsants. "
|3.||Colorectal Neoplasms (Colorectal Cancer)
01/01/2000 - "A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer."
01/01/1997 - "Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma."
01/01/2000 - "To perform a phase II trial of pyrazoloacridine (PZA), a novel DNA intercalator, in patients with metastatic colorectal carcinoma and no previous therapy. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
02/01/2002 - "The Gynecologic Oncology Group performed a Phase II study to determine the response rate of pyrazoloacridine (PZA) in patients with platinum-resistant ovarian cancer. "
02/01/2002 - "Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study."
01/01/2002 - "Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study."
|5.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/01/2002 - "The Gynecologic Oncology Group performed a phase II study to determine the response rate to pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. "
08/01/2002 - "A phase II trial of pyrazoloacridine (PZA) in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study."
01/01/2001 - "The Gynecologic Oncology Group performed a Phase II study to determine the response rate of Pyrazoloacridine (PZA) in patients with advanced, persistent or recurrent squamous carcinoma of the cervix. "
01/01/2001 - "A phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix--a Gynecologic Oncology Group Study."
|2.||Anticonvulsants (Antiepileptic Drugs)
|3.||NSC 366140 (pyrazoloacridine)
|5.||DNA (Deoxyribonucleic Acid)
|8.||Multidrug Resistance-Associated Proteins
|2.||Heterologous Transplantation (Xenotransplantation)